Rapt Therapeutics, Inc.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: US75382E1091

USD

34.47

2.14 (6.62%)

Dec 04

NAS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Kiniksa Pharmaceuticals Ltd.

PetIQ, Inc.

Tarsus Pharmaceuticals, Inc.

Travere Therapeutics, Inc.

Phathom Pharmaceuticals, Inc.

Viridian Therapeutics, Inc.

Amneal Pharmaceuticals, Inc.

NewAmsterdam Pharma Co. NV

Arcturus Therapeutics Holdings, Inc.

Rapt Therapeutics, Inc.

Genelux Corp.

Why is Rapt Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Rapt Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Rapt Therapeutics, Inc.

259.06%

1.00

681.83%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-179.74%

EBIT to Interest (avg)

-95.52

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.87

EV to EBIT

0.18

EV to EBITDA

0.19

EV to Capital Employed

-22.18

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-65.69%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(HY)

Higher at USD -34.81 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

PRE-TAX PROFIT(Q)

At USD -17.64 MM has Grown at 39.43%

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Rapt Therapeutics, Inc.

Net Profit

Higher at USD -34.81 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Pre-Tax Profit

At USD -17.64 MM has Grown at 39.43%

over average net sales of the previous four periods of USD -29.13 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales